Evidencia actual de la plasmaféresis frente a la inmunoglobulina intravenosa en formas graves del síndrome de Guillain-Barré
Open Access
- 3 January 2026
- journal article
- Published by Editorial Kronos in Atlas Research Journal
- Vol. 4 (1) , 194-213
Abstract
Introduction: Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy that, in severe forms, may lead to respiratory failure, autonomic dysfunction, and long-term disability. Plasma exchange (PE) and intravenous immunoglobulin (IVIg) are standard immunomodulatory therapies; however, questions remain regarding their comparative performance and feasibility across healthcare settings. Objective: To synthesize recent scientific evidence on the efficacy, safety, and clinical applicability of plasma exchange versus IVIg in severe GBS. Methodology: A qualitative documentary and analytical review (2022–2026) were conducted using PubMed, Scopus, Web of Science, and Cochrane Library databases. Systematic reviews, meta-analyses, observational studies, and clinical reviews were included. Findings were organized into comparative matrices and critically interpreted. Results: Current evidence indicates comparable overall efficacy between PE and IVIg in key outcomes, including clinical improvement, duration of mechanical ventilation, and length of hospital stay. Contextual differences were identified: IVIg is easier to administer and generally better tolerated, whereas PE may be more cost-effective in certain settings and remains a viable option in resource-limited environments. Early treatment initiation, particularly with IVIg, is associated with improved functional recovery. Conclusions: No consistent therapeutic superiority is observed. Treatment selection should be individualized according to disease severity, timing of intervention, patient risk profile, and institutional resources.Keywords
This publication has 11 references indexed in Scilit:
- Plasma exchange following immunoglobulins for Guillain-Barré-Syndrome: a persisting problematic practice?Frontiers in Neurology, 2026
- New insights in the immune treatment of Guillain–Barré syndromeCurrent Opinion in Neurology, 2025
- Plasma Exchange versus Intravenous Immunoglobulin for the Treatment of Guillain Barre Syndrome. (P4-8.006)Neurology, 2025
- Immunoglobulin unresponsive Guillain-Barré syndrome: rinse or repeat? A systematic reviewBMJ Neurology Open, 2025
- Timing of intravenous immunoglobulin treatment and outcome in Guillain–Barré syndrome: Is time nerve?Muscle & Nerve, 2024
- Treatment Efficacy of Plasmapheresis Versus Intravenous Immunoglobulin in Guillain-Barré Syndrome Management: A Systematic ReviewCureus, 2024
- Assessing the comparative efficacy of plasmapheresis and Intravenous immunoglobulin in myasthenia gravis treatment: A systematic review and meta-analysisJournal of Clinical Neuroscience, 2024
- Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barré syndrome (GBS) in patients with severe symptoms: A systematic review and meta-analysiseNeurologicalSci, 2023
- Alternative Therapies to Immunoglobulin for Guillain-Barré SyndromeCanadian Journal of Health Technologies, 2023
- Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: a systematic literature reviewTherapeutic Advances in Neurological Disorders, 2023